Tonix is recruiting individuals for research studies in:
Fibromyalgia

Click here for more information.

Changing the Landscape

Millions of Americans suffer from central nervous system disorders. Tonix Pharmaceuticals is developing next-generation medicines to help.

Learn more

Latest News

Tonix Pharmaceuticals to Present at the 18th Annual BIO CEO & Investor Conference

• February 2, 2016 • 7:05 AM EST

Read more

Management Team

Our experienced team has a strong track record of success in drug approvals and value creation.

View Management

Clinical Pipeline

Tonix's lead product candidate,TNX-102 SL, is being developed for the treatment of fibromyalgia. Tonix is also developing TNX-102 SL for the treatment of PTSD and TNX-201 for the treatment of episodic tension-type headache.

View Pipeline

About Tonix Pharmaceuticals

Tonix is developing next-generation medicines for common disorders of the central nervous system, including fibromyalgia, post-traumatic stress disorder, and episodic tension-type headache. These disorders are characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and significant economic burden.

Learn more about tonix